and then HGEN actually meets there primary endpoint and has a mortality rate of 13.9% in the placebo arm. I guess that's what we get for accepting the worst of the worst patients.

But not stat sig in mortality.

Quote:

---

Although this study was not powered to demonstrate a difference in mortality, a favorable trend in mortality was observed: 9.6% (95%CI: 6.4-14.2) in the lenzilumab arm compared with 13.9% (95%CI: 10.1-19.0) in the placebo arm (HR: 1.39; 95%CI: 0.82-2.39; p=0.2287).

---